## Venexia M Walker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/30866/publications.pdf

Version: 2024-02-01

29 papers 1,301 citations

623699 14 h-index 27 g-index

57 all docs

57 docs citations

57 times ranked

1931 citing authors

#	Article	IF	CITATIONS
1	Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nature Genetics, 2020, 52, 1122-1131.	21.4	298
2	Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. International Journal of Epidemiology, 2017, 46, 2078-2089.	1.9	123
3	Linked electronic health records for research on a nationwide cohort of more than 54 million people in England: data resource. BMJ, The, 2021, 373, n826.	6.0	98
4	Cardiometabolic Traits, Sepsis, and Severe COVID-19. Circulation, 2020, 142, 1791-1793.	1.6	93
5	Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Research, 2021, 6, 16.	1.8	90
6	Repurposing antihypertensive drugs for the prevention of Alzheimer's disease: a Mendelian randomization study. International Journal of Epidemiology, 2020, 49, 1132-1140.	1.9	55
7	Using the MR-Base platform to investigate risk factors and drug targets for thousands of phenotypes. Wellcome Open Research, 2019, 4, 113.	1.8	52
8	Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England. PLoS Medicine, 2022, 19, e1003926.	8.4	51
9	Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Research, 2021, 6, 16.	1.8	48
10	Prioritizing the Role of Major Lipoproteins and Subfractions as Risk Factors for Peripheral Artery Disease. Circulation, 2021, 144, 353-364.	1.6	47
11	Using the MR-Base platform to investigate risk factors and drug targets for thousands of phenotypes. Wellcome Open Research, 2019, 4, 113.	1.8	47
12	Trans-ethnic Mendelian-randomization study reveals causal relationships between cardiometabolic factors and chronic kidney disease. International Journal of Epidemiology, 2022, 50, 1995-2010.	1.9	39
13	Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis. PLoS Medicine, 2022, 19, e1003897.	8.4	30
14	Association Between Genetic Variation in Blood Pressure and Increased Lifetime Risk of Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2027-2034.	2.4	24
15	Comparison with randomized controlled trials as a strategy for evaluating instruments in Mendelian randomization. International Journal of Epidemiology, 2020, 49, 1404-1406.	1.9	18
16	Genetically Predicted Blood Pressure and Risk of Atrial Fibrillation. Hypertension, 2021, 77, 376-382.	2.7	16
17	Comparison of Antihypertensive Drug Classes for Dementia Prevention. Epidemiology, 2020, 31, 852-859.	2.7	14
18	Power calculator for instrumental variable analysis in pharmacoepidemiology. International Journal of Epidemiology, 2017, 46, 1627-1632.	1.9	13

#	Article	IF	CITATIONS
19	Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort. Heart, 2022, 108, 923-931.	2.9	12
20	Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer's and other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice Research Datalink. BMJ Open, 2016, 6, e012044.	1.9	10
21	Separating the direct effects of traits on atherosclerotic cardiovascular disease from those mediated by type 2 diabetes. Diabetologia, 2022, 65, 790-799.	6.3	9
22	What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink. Alzheimer's Research and Therapy, 2018, 10, 51.	6.2	8
23	Using Mendelian randomisation to identify opportunities for type 2 diabetes prevention by repurposing medications used for lipid management. EBioMedicine, 2022, 80, 104038.	6.1	7
24	Mendelian randomization applied to pharmaceutical use: the case of metformin and lung cancer. International Journal of Epidemiology, 2020, 49, 1410-1411.	1.9	5
25	Phenotypic Causal Inference Using Genome-Wide Association Study Data: Mendelian Randomization and Beyond. Annual Review of Biomedical Data Science, 2022, 5, 1-17.	6.5	5
26	Little genomic support for Cyclophilin A-matrix metalloproteinase-9 pathway as a therapeutic target for cognitive impairment in APOE4 carriers. Scientific Reports, 2022, 12, 1057.	3.3	4
27	The consequences of adjustment, correction and selection in genome-wide association studies used for two-sample Mendelian randomization. Wellcome Open Research, 0, 6, 103.	1.8	3
28	Letter regarding, "Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses†Journal of Cancer Research and Clinical Oncology, 2021, 147, 2171-2173.	2.5	2
29	Pharmacoepidemiology in pregnancy: analysis protocol for an observational cohort study in the UK Clinical Practice Research Datalink. Wellcome Open Research, 0, 7, 12.	1.8	O